Sofetabart Mipitecan
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Sofetabart Mipitecan, covering 2026-04-17 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer [Phase 3]